Extended-Spectrum-β-Lactamase-Producing <I>Proteus mirabilis</I>: Laboratory-Based Surveillance in Cooperation with 12 Clinical Laboratories in the Kinki Region of Japan

• NAKAMURA Tatsuya

  Clinical Central Laboratory, Kansai Medical University Hospital

• KOMATSU Masaru

  Department of Clinical Pathology, Tenri Hospital

• SHIMAKAWA Kouichi

  Infection center, Shionogi Biomedical Laboratories

• SUEYOSHI Noriyuki

  Clinical Laboratory, Social Insurance Shiga Hospital

• SATOH Kaori

  Department of Medical Technology, Kinki University School of Medicine

• TOYOKAWA Masahiro

  Laboratory for Clinical Investigation, Osaka University Hospital

• NISHIO Hisaaki

  Clinical Laboratory, Shiga Medical Center for Adults

• WADA Yasunao

  Clinical Laboratory, Hyogo Medical University Hospital

• ORITA Tamaki

  Clinical Laboratory, Takarazuka Municipal Hospital

• KOFUKU Tomomi

  Clinical Laboratory, Hyogo Prefectural Amagasaki Hospital

• SAKAMOTO Masako

  Clinical Laboratory, The Research Foundation for Microbial Diseases of Osaka University

• OKAMOTO Kiyotaka

  Clinical Laboratory, Osaka Police Hospital

• AKAGI Masahiro

  Clinical Laboratory, Osaka Police Hospital

• KINOSHITA Shohiro

  Clinical Laboratory, Kobe University Hospital

Bibliographic Information

Other Title

• 近畿地区における<I>Proteus mirabilis</I>のESBL産生菌分離状況と疫学解析
• 近畿地区におけるProteus mirabilisのESBL産生菌分離状況と疫学解析
• キンキ チク ニ オケル Proteus mirabilis ノ ESBL サンセイキン ブンリ ジョウキョウ ト エキガク カイセキ
• Extended-Spectrum-^|^beta;-Lactamase-Producing Proteus mirabilis: Laboratory-Based Surveillance in Cooperation with 12 Clinical Laboratories in the Kinki Region of Japan

Abstract

We studied 247 strains of Proteus mirabilis collected during the 6 months from November 2003 to April 2004 from 12 clinical laboratories in the Kinki region of Japan for the production of extended-spectrum β-lactamase (ESBL).Eighteen strains (7.3%) showed MICs for cefpodoxime of≥2μg/mL and 13 strains (5.2%) were positive for the double-disk synergy test. Susceptibility depended on genotype. MICs for cefepime, cefozopran, and cefpirome were high (≥8μg/mL), and that for ceftazidime was low (0.12-0.5μg/mL). Meropenem showed the lowest MIC (≤0.03-0.25μg/mL) of the calbapenems, while other calbapenems showed somewhat higher values (0.5-2μg/mL). The MIC of tazobactam/piperacillin was also relatively low (≤0.25-1μg/mL). Analysis of the ESBL genotype by the polymerase chain reaction showed that 12 of 13 strains were CTX-M2 types. CTX-M9 was detected in a single laboratory. The clinical background showed 5 strains in urine samples. Twelve of 13 strains were detected in patients with minimal devices use. No symptoms were found in most cases of established syndrome. Analysis of PCR fingerprint profiles of random amplified polymorphic DNA patterns showed that 6 of 7 strains from hospital 1 showed the same pattern, and 5 of 5 strains from hospital 13 showed the same pattern, suggesting the nosocomial spread of P. mirabilis in each hospital.

Journal

• Kansenshogaku Zasshi

  Kansenshogaku Zasshi 80 (3), 231-237, 2006

  The Japanese Association for Infectious Diseases

Keywords

• Proteus mirabilis
• extended-spectrum β-lactamase(ESBL)
• CTX-M2
• random amplified polymorphilic DNA

Details

• CRID: 1390282680025498880
• NII Article ID: 10031032085
• NII Article ID: 130004331308
• NII Article ID: 10018060489
• NII Book ID: AN00047715
• DOI: 10.11150/kansenshogakuzasshi1970.80.231
• ISSN: 1884569X
• ISSN: 03875911
• NDL BIB ID: 7945481
• PubMed: 16780129
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I7945481
• Web Site: https://search.jamas.or.jp/link/ui/2006216376
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
• Abstract License Flag: Disallowed